Drug-coated balloon versus drug-eluting stent treatment for coronary artery narrowing
Compares drug-coated balloon and stent-only treatment for adults with newly narrowed heart arteries.
Key facts
- Who runs it
- Korea University Guro Hospital
- Where
- Seoul, South KoreaSee the 4 sites
- Trial code
- Registry title
- Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Percutaneous Coronary Intervention Strategies
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 9 Nov 2026
- Expected to end
- 30 Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Drug-coated balloon-based intervention
- Drug-eluting stent-based intervention
- Record updated
- 1 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who need a procedure to open a narrowed heart artery because of angina or a heart attack. It compares a drug-coated balloon with a drug-eluting stent.
- Age
- 19 years or older
- Sex
- Women and men can join.
- Disease stage
- A narrowed heart artery (target or culprit lesion) that can be treated with either a drug-coated balloon or a drug-eluting stent. The artery must be at least 2.25 mm wide. The need for treatment is due to angina or a heart attack.
Main reasons for not taking part
- Active bleeding, a clear bleeding tendency, or a clotting disorder
- Allergy or a reason not to use aspirin, P2Y12 inhibitors, or parts of the stent or balloon
- Shock of the heart that does not respond to treatment
- Narrowing inside an old stent, in a bypass graft, a fully blocked artery, or left main artery disease
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Adults aged 19 years or older
- Patients requiring coronary revascularization for angina or myocardial infarction
- A target or culprit lesion suitable for both DCB and DES treatment
- Reference vessel diameter of the target or culprit lesion ≥2.25 mm
- Voluntary written informed consent after an explanation of the study objectives and procedures
- For foreign nationals, ability to communicate in Korean
Who cannot take part
- Active bleeding, a clinically significant bleeding tendency, or a coagulation disorder
- Hypersensitivity or a contraindication to aspirin, P2Y12 inhibitors, or components of a DES or DCB (drug, polymer, or metal)
- Angiographic exclusion:; Target lesion in ISR (in-stent restenosis); Target lesion in a bypass graft; Chronic total occlusion; Left main coronary artery disease
- History of stent thrombosis
- Expected survival of less than 1 year because of comorbid illness
- Left ventricular ejection fraction ≤20%
- Refractory cardiogenic shock
- Pregnancy or breastfeeding
- In the investigator's judgment, unsuitable for study participation for clinical or anatomical reasons
Where in South Korea
- Hanil General HospitalSeoul, South KoreaContact: Ji Bak Kim, MD, PhDNot yet recruiting
- Hanyang University Seoul HospitalSeoul, South KoreaContact: Woohyeun Kim, MD, PhDNot yet recruiting
- Korea University Anam HospitalSeoul, South KoreaContact: Jung-Joon Cha, MD, PhDNot yet recruiting
- Korea University Guro HospitalSeoul, South KoreaContact: Dong Oh Kang, MD, PhDNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to find out whether a treatment strategy based on a drug-coated balloon (DCB) achieves coronary artery function at 6 months that is not worse than a strategy using only drug-eluting stents (DES) by more than a prespecified amount. The study will enroll adults undergoing percutaneous coronary intervention (PCI) for a new coronary artery narrowing (de novo lesion).
Read full original descriptionShow less
The main questions are:
1. Is fractional flow reserve (FFR) at 6 months noninferior after DCB-based PCI compared with DES-only PCI? FFR is a pressure-based measure used to assess blood flow through a coronary artery. 2. Does the DCB-based strategy reduce the number and total length of stents implanted? 3. What cardiovascular events or medical problems, such as cardiovascular death, myocardial infarction, repeat coronary procedures, or bleeding, occur during follow-up?
Investigators will randomly assign 100 participants to one of two treatment strategies. In the DCB-based group, the lesion will first be prepared with a balloon. A DCB will be used if lesion preparation produces a suitable result; a DES may be implanted if needed to achieve a safe and adequate result. In the DES-only group, the lesion will be treated with a DES.
Participants will:
1. Receive treatment according to their assigned strategy. 2. Undergo follow-up coronary angiography and FFR measurement at approximately 6 months. For clinical reasons, this examination may take place up to 9 months after the procedure. 3. Be followed for cardiovascular events through 12 months after randomization.
The 2 groups in the trial
- DCB-based PCI groupTreatment being tested
In the DCB-based PCI group, lesion preparation may include conventional, non-compliant, cutting, or scoring balloons and, when needed, other calcium-modification techniques. An adequately prepared lesion has expansion with a balloon-to-vessel diameter ratio of at least 0.90, residual diameter stenosis of 30% or less, TIMI grade 3 flow, and no flow-limiting dissection or risk of vessel closure. When these conditions are met, the operator will use a paclitaxel-coated DCB (SeQuent Please NEO), sized approximately 1:1 to the reference vessel and covering the prepared segment. DCB delivery within 30 seconds and inflation for 30-60 seconds are recommended when clinically tolerated. DES implantation is permitted for inadequate flow, residual stenosis greater than 30%, substantial recoil, a major dissection, or another procedural reason requiring immediate stenting. Such stenting is part of the assigned DCB-based strategy, not a treatment crossover.
Treatment: Drug-coated balloon-based intervention
- DES-only PCI groupExisting treatment, for comparison
In the DES-only PCI group, the target or culprit lesion will be treated with a contemporary newer-generation DES according to clinical practice.
Treatment: Drug-eluting stent-based intervention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Percutaneous Coronary Intervention Strategies (FLOW-DCB): A Multicenter, Prospective, Randomized Controlled, Non-inferiority Trial
- Plain-language title
- Drug-coated balloon versus drug-eluting stent treatment for coronary artery narrowingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 1 October 2026